These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35803353)

  • 1. Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England.
    Thomas C; Mandrik O; Whyte S
    Prev Med; 2022 Sep; 162():107131. PubMed ID: 35803353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic Inequalities in Colorectal Cancer Screening in Korea, 2005-2015: After the Introduction of the National Cancer Screening Program.
    Mai TTX; Lee YY; Suh M; Choi E; Lee EY; Ki M; Cho H; Park B; Jun JK; Kim Y; Oh JK; Choi KS
    Yonsei Med J; 2018 Nov; 59(9):1034-1040. PubMed ID: 30328317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decomposing socio-economic inequality in colorectal cancer screening uptake in England.
    Solmi F; Von Wagner C; Kobayashi LC; Raine R; Wardle J; Morris S
    Soc Sci Med; 2015 Jun; 134():76-86. PubMed ID: 25917138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
    Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
    Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.
    De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C
    Value Health; 2018 Jun; 21(6):685-691. PubMed ID: 29909873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
    Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients.
    Yeoh A; Mannalithara A; Ladabaum U
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):507-519. PubMed ID: 35940514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.
    Cross AJ; Robbins EC; Pack K; Stenson I; Kirby PL; Patel B; Rutter MD; Veitch AM; Saunders BP; Little M; Gray A; Duffy SW; Wooldrage K
    Health Technol Assess; 2022 May; 26(26):1-156. PubMed ID: 35635015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 15. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
    Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
    Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.